TORONTO, July 05, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI) (FRANKFURT:75M) (OTCQB:MRRCF)
(“Maricann” or the “Company”) is pleased to announce that the Company has entered into a supply agreement with the Alberta Gaming,
Liquor & Cannabis Commission (AGLC) to provide the Alberta market with cannabis products.
The Company is in dialogue with several other provinces for both 2018 and 2019 and will make announcements as
permitted if and when such agreements are executed. While there are no assurances that additional supply agreements will be
executed, ongoing discussions with certain provinces have confirmed a high regard for the Company’s capabilities and
competitiveness consistent with that of much larger industry players.
Langton Facility Expansion
Construction on the expansion of the Company's facility at 138 8th Concession Road, Langton, Ontario (the
"Langton Facility') is continuing to progress. By mid-November, 2018 (subject to receipt of the applicable licenses from
Health Canada), Maricann expects to be capable of producing 706kg of dried cannabis per week in Phase 1 of the expansion of its
Langton Facility. By April 2019, Maricann expects to be capable of producing 2,023kg of dried cannabis per week assuming building
permits, long lead items, such as HVAC equipment are delivered on time, at its Langton Facility.
Germany Operations Update
Maricann has completed the retrofit to 4,600 sqm (approximately 49,000 sq. ft.) of its Ebersbach facility in
Germany for narcotics import and wholesale. Site inspections by European Medicines Agency authorities are now complete, with
no significant findings noted. The Company will provide a further update if and when final approval from regulatory
authorities is achieved. This certification, if obtained, will permit Maricann to import its own and others' EMA-GMP approved
products for distribution in Germany and the rest of Europe, where legal, maintaining profit margin, that in most cases totals 50%
of wholesale price.
Malta and VesiSorb Update
As anticipated, Maricann has received confirmation from Malta Enterprise (the country's official economic
development agency) in the form of a Letter of Intent, to move ahead with licensing of finished goods production facilities for
medical cannabis. Malta comprises an integral part of Maricann’s long-term development strategy, with finished goods
manufacturing, including its patented VesiSorb CBD and THC softgels to take place in Malta. VesiFact produces the world’s
first dosage controlled soft gel capsules with enhanced bio-availability and rapid onset.
Maricann has now manufactured consistent THC distillate at its Langton Ontario facilities, a building block for
future recreational market products, and consistent finished dose pharmaceutical products. Maricann utilized Thin Film
Distillation to process the material.
“We continue to execute and develop all aspects of the Company according to our plan, achieving forward momentum
for our shareholders, with a focus on maintaining baskets of margin by developing business units and additional capabilities as a
company for a fraction of the expense seen in the sector. Governmental regulatory agencies continue to endorse our company by
entrusting us as one of a handful of companies with medical cannabis licensure and product supply. We are proud of our
progress to date and will continue to drive shareholder value, over the long term by strategically segmenting our business by
geography, strategic investments, quality and scientifically differentiated products, developed by proficient and qualified
experts,” stated Ben Ward, CEO.
Special Committee Review
Further to the work of the Special Committee of the board of directors (the "Special Committee"), the Company
has broadened and strengthened its policy on trading blackouts and is preparing to adopt enhanced approval processes for trading by
Board members and senior management.
Consistent with the high level of strategic activity in the sector, the Company under the direction of the
Special Committee has discussed, and continues to discuss, various potential strategic transactions, including both business
combinations, joint ventures and significant supply arrangements with various domestic and international parties. The Company
intends to continue to monitor industry developments and may have further discussions in respect of potential strategic
transactions. At this time there are no specific transactions for the Company to disclose.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was
founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario
where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from
the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland.
Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq.
m) build-out and will continue to pursue new opportunities in Europe.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news
release.
Forward Looking Information
Certain statements in this press release contain forward-looking statements, including, without limitation
with respect to (i) the execution of additional supply agreements, (ii) anticipated production at the Langton Facility, (iii)
receipt of regulatory approvals in German, (iv) the nature of operations in Malta and the use of the VesiSorb technology and (v)
the entering into of one or more strategic transactions, which can be identified by the use of forward-looking terminology such as
“believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, or
any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that
potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their
nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could
cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect
the view of the Company with respect to future events, and are based on information currently available to the Company and on
assumptions, which it considers reasonable. Management cautions readers that the assumptions relative to the future events, several
of which are beyond management’s control, could prove to be incorrect, given that they are subject to certain risk and
uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to
differ from current expectations include, among other things: risks inherent to the expansion project; fluctuations in operating
results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees;
fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; expectations regarding
market demand for particular products and the dependence on new product development; the impact of market change; and the impact of
price and product competition, the ability to secured applicable licenses as well as other risks discussed in its latest annual
information form and other disclosure documents of the Company available at www.sedar.com. Management disclaims any intention or
obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise,
except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking
information.
For more information about Maricann, please visit our website at www.maricann.com
CONTACT INFORMATION
Investor Relations
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665
Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274
European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland
